汇得科技(603192.SH):拟推329.50万股限制性股票激励计划
格隆汇9月10日丨汇得科技(603192.SH)公布2024年限制性股票激励计划,本激励计划拟向激励对象授予的限制性股票数量为329.50万股,约占本激励计划公吿时公司股本总额13,866.6667万股的2.38%。其中首次授予限制性股票数量263.60万股,约占本激励计划草案公吿时公司股本总额13,866.6667万股的1.90%,占本次授予权益总额的80%;预留限制性股票数量65.90万股,约占本激励计划草案公吿时公司股本总额13,866.6667万股的0.48%,约占本计划拟授予限制性股票总数的20%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.